Background
==========

Breast cancer is the second most common cancer worldwide today, and by far the most common cancer in women in many countries, with an estimated 1.4 million new cases and 458,000 deaths around 2008 annually \[[@B1]\]. Although breast cancer incidence and mortality rates in the western countries have been decreasing or stable during the past 2 to 3 decades, both rates have been increasing rapidly in many developing countries \[[@B2]\]. In China, according to the most updated but limited cancer registries, breast cancer became the most important incident female cancer and ranked the 6^th^leading cause of death in Chinese women in year 2006 \[[@B3]\]. No nation-wide representative data of breast cancer in China was available.

The etiology of breast cancer remains unknown. Due to the lack of evidence, primary preventive strategies for breast cancer have commanded little attention. Rather, the focus has been on improving prognosis (outcome) for women developing breast cancer, through early detection and improved treatment (surgical, radiotherapy, hormonal and chemotherapeutic measures). Current therapeutic options for breast cancer in China are varied, with treatment allocation generally dependent on the accessible resources, the patient\'s economic status and the tumor burden. In the recent decades, when estrogen receptor (ER) status was approved to be an important treatment and prognostic factor, targeted therapy has become encouraging in breast cancer treatment \[[@B4]\]. But due to limited access of updated guidelines and resources, information regarding the application of breast cancer treatment with this new therapy within China is not clear.

The nation-wide multi-center 10-year (1999-2008) retrospective clinical epidemiological study of female breast Cancer in China was a retrospective study of patients with pathology confirmed primary breast cancer from 7 geographic regions across China (North, North-East, Central, South, East, North-West, and South-West). The aims of this study were to document (1) the sociodemographic characteristics and the distribution of some risk factors among Chinese female breast cancer cases; (2) the clinical characteristics of female breast cancer and (3) current treatment options for Chinese female breast cancer patients.

Methods
=======

Study Design
------------

This study was a hospital-based multi-center 10 year retrospective study of randomly selected pathology confirmed primary female breast cancer cases via medical chart review.

Selection of Regions and Hospitals
----------------------------------

As described previously, China was stratified into 7 geographic regions according to the traditional administrative district definition; these regions extend over the majority of the country and represent different levels of breast cancer burden. One tertiary hospital from each region was selected to provide the required study cases.

Convenient sampling was used to choose the participant hospitals with inclusion in the study on the basis that (1) they were one of the best leading hospitals at the tertiary level and had regional referral centers providing pathology diagnosis, surgery, radiotherapy, medical oncology, and routine follow-up care for patients with breast cancer; (2) visiting patients were from different parts of the region; and (3) the breast cancer screening practices, when used, should be in accordance with Chinese national standards. A total of 7 hospitals were involved in the study, with Cancer Hospital/Institute, Chinese Academy of Medical Sciences (CICAMS) as the lead center for the overall coordination of this research in China \[Figure [1](#F1){ref-type="fig"}\].

![**Geographic distribution of sites included in the study**. 1: Cancer Institute/ Hospital, Chinese Academy of Medical Sciences 2: Liaoning Cancer Hospital 3: Second Xiangva Hospital, Central South University 4: Guangdong Sun Yat-Sen University Cancer Center 5: Zhejiang Cancer Hospital 6: First Affiliated Hospital of Xi\'an Jiaotong University 7: Sichuan Cancer Hospital.](1471-2407-11-364-1){#F1}

Patients
--------

This study included pathology confirmed female primary breast cancer inpatients in one randomly selected month each from year 1999 to 2008. January and February were excluded for randomization because Chinese traditional spring festival is always in these two months and there are much fewer inpatients during the time period. In order to avoid selection bias, an enrolment scheme was adopted using alternating prespecified month of inpatient admission from year to year. For example, in the first year (1999) of data collection, pathology confirmed primary breast cancer patients admitted to inpatient treatment in March would be enrolled into the study; in the second year (2000), inpatients admitted in April would be enrolled. All cases within the selected month were reviewed and patient\'s information was collected based on the designed case report form (CRF). In each selected month, if inpatients admissions were less than 50 in that year, more cases from the neighbouring months were reviewed until the total number in that year reaches 50. Whereas, if inpatients number in the selected month exceeded 50, all cases should be reviewed. To ensure that the national study was geographically representative, it was designed to include patients enrolled at sites from all 7 traditional regions across China \[Figure [1](#F1){ref-type="fig"}\].

All patients enrolled in this study must meet 3 key inclusion criteria: (1) pathology confirmed primary breast cancer (2) inpatient admission date was within the selected month in the study hospital and (3) received or receiving treatment (surgery, medical oncology, radiotherapy) for breast cancer.

This study was approved by the Cancer Foundation of China Institutional Review Board. Patient consent was not required for this study because there were no anticipated risks for the participants of the study. The data was stripped of any patient identifiers per the approved procedures. De-identified data were maintained on secure database. Only research team members have access to the data. All data will be reported in aggregate.

Pathologic Diagnostic Criteria
------------------------------

Histological subtype was based on the 1981 and 2003 WHO histological classification criteria \[[@B5],[@B6]\]. Staging of breast cancer was done according to the AJCC TNM staging system of year 1997 and after \[[@B7],[@B8]\].

Data Collection and Quality Control
-----------------------------------

The following data were systematically collected for all enrolled patients via medical chart review: (1) general information including date of diagnosis, visits to other health care professionals, inpatient admission date, diagnosis at admission, inpatient discharge date, and discharge outcome; (2) demographic characteristics at the time of diagnosis/admissions including age, occupation, height, weight, education and marital status; (3) breast cancer risk factors such as age at menarche, age at menopause, age at marriage, age at first delivery, number of live birth, breastfeeding history, family history of breast cancer, use of oral contraception, history of smoking and alcohol drinking; (4) results of the clinical breast examination (CBE); (5) results of the diagnostic imaging including mammography, ultrasound and magnetic resonance imaging (MRI); (6) the use of currently available surgery approaches; (7) the use of radiotherapy for breast cancer; (8) the use of chemotherapy for breast cancer, including adjuvant chemotherapy and neoadjuvant chemotherapy; (9) the use of molecular targeted therapy for breast cancer; (10) pathological characteristics including pre-surgery cytology and pathologic examinations, intraoperative pathologic evaluation, post-surgery pathology, estrogen and progesterone receptor expressions and human epidermal growth factor receptor 2(HER-2) expression etc. Also, the ranking and number of the 10 most dominant cancer patients visits were also collected.

All above information was extracted from medical charts to the designed CRF by local clerks after training. Then two data input clerks from each site were recruited to independently double-enter data from the paper to computer based database (FoxPro). All finished double-entry databases were sent to CICAMS for validation by running EpiData. Any inconsistency found by CICAMS between the two databases was reported to the local clerks for adjudication until the databases agreed. As a final inspection, one of databases was chosen to undergo a final consistency check. Logical errors (e.g. a woman had no surgery yet had intraoperative frozen section diagnosis) were again reported back to the local sites, and the local collaborators reviewed the original medical chart again. After checking with the original medical record, the local staff sent the revised database back to CICAMS for a final analysis. During the consistency check, 5% of the medical charts were randomly selected based on the study ID and sent to CICAMS for quality control review.

Sample Size
-----------

Sample size requirements for the Chinese regional sites were a minimum of 50 patients per site per year between 1999 and 2008. To capture treatment and clinical outcomes in breast cancer over 10 years, it was mandatory to collect a total number of no less than 500 cases per hospital in time span. Pooling of data across all sites in China was employed to adequately describe disease and treatment characteristics across the country.

Data Analysis
-------------

Frequencies were run on variables related to demographic, reproductive, clinical and pathologic characteristics to determine their distribution overall and among early stage (ES) (stage I & II) compared to late stage (LS) (stage III & IV). Quantitative variables were calculated by the mean or median depending on the data distribution. The differences in distribution of variables between ES and LS were examined using Mantel-Haenszel chi-square tests and Fisher\'s exact tests to obtain *p*-values for the test of no-association.

SPSS statistical software version 17.0 was used to analyze the data. Statistical significance was assessed by two-tailed tests with α level of 0.05.

Results
=======

A total number of 4,267 breast cancer inpatients across the various geographic regions in the study were collected. Of them, 48 cases were excluded for analysis because they were not from the selected months. Seven were deleted because the final pathological diagnoses belonged to benign tumors instead of malignancy. One case was disqualified because the \'unknown\' items exceeded 50% of the CRF. A final total number of 4,211 cases from seven sites across China were included for final analysis. Table [1](#T1){ref-type="table"} illustrates the case distribution and proportion by region and year.

###### 

Case distribution by region and year

  Year        North   North-East   Central   South      East   North-West   South-West   Total                                                                       
  ----------- ------- ------------ --------- ---------- ------ ------------ ------------ ----------- ------ ---------- ------ ----------- ------ ----------- ------- -----------
  **2008**    1649    91(5.5)      1632      82(5.0)    647    73(11.3)     782          75(9.6)     1400   81(5.8)    894    45(5.0)     508    50(9.8)     7512    497(6.6)
  **2007**    1390    110(7.9)     1486      134(9.3)   532    66(12.4)     835          74(8.9)     1262   83(6.6)    458    51(11.1)    404    50(12.4)    6367    568(8.9)
  **2006**    1208    87(7.2)      1377      95(6.9)    368    60(16.3)     781          53(6.8)     1144   68(5.9)    215    49(22.8)    357    50(14.0)    5450    462(8.5)
  **2005**    1108    60(5.4)      1195      75(6.3)    330    55(16.7)     734          59(8.0)     1008   58(5.8)    465    49(10.5)    356    50(14.0)    5196    406(7.8)
  **2004**    902     50(5.5)      1152      96(8.3)    340    51(15.0)     620          53(8.6)     1065   64(6.1)    313    53(16.9)    322    50(15.5)    4714    417(8.9)
  **2003**    715     50(7.0)      1097      78(7.1)    294    49(16.7)     527          59(11.2)    875    52(5.9)    179    53(29.6)    265    49(18.5)    3952    390(9.9)
  **2002**    764     41(5.4)      1044      51(4.9)    227    46(20.3)     397          58(14.6)    593    51(8.6)    157    44(28.0)    207    50(24.2)    3389    341(10.1)
  **2001**    681     52(7.6)      982       74(7.5)    144    46(31.9)     374          58(15.5)    545    50(9.2)    153    47(30.7)    380    50(13.2)    3259    377(11.6)
  **2000**    587     50(8.5)      874       52(6.0)    106    48(45.3)     289          55(19.0)    461    50(10.9)   136    45(33.1)    318    50(15.7)    2771    350(12.6)
  **1999**    532     50(9.4)      831       95(11.4)   139    52(37.4)     298          60(20.1)    392    49(12.5)   156    47(30.1)    242    50(20.7)    2590    403(15.6)
  **Total**   9536    641(6.7)     11670     832(7.1)   3127   546(17.5)    5637         604(10.7)   8745   606(6.9)   3126   483(15.5)   3359   499(14.9)   45200   4211(9.3)

N\* number of the actual breast cancer visits each year from year 1999-2008;

n\*\* number of breast cancer cases collected per protocol.

Patients Characteristics
------------------------

Of the total 4,211 cases that were identified over a period of 10 years from 1999 to 2008, the mean age at diagnosis and age range for all breast cancer patients was 48.7 years (s.d. = 10.5 yrs) and 21-86 years, respectively. Among all cases, 2,554 (60.6%) were in ES with a mean age of 49.1 years (s.d. = 10.4 yrs) while 901 (21.4%) were in LS with a mean age of 48.8 years (s.d. = 10.3 yrs). The majority (67.6%) of breast cancer patients were of normal Body Mass Index (BMI). More breast cancer cases presented in LS (59.6%) were manual workers (*P*\< 0.001) and the proportion of receiving higher education (university and above) was much less compared with the ES group (14.2% vs. 21.3%, *P*= 0.008). The percentage distribution of smoking, alcohol drinking and family history of breast cancer differed between women presented in ES and LS (*P*\< 0.050) (Table [2](#T2){ref-type="table"}). More breast cancer cases (7.6% vs. 6.3%. *P*= 0.030) presented in LS reported to have the first delivery at or older than 30 years of age and the percentage distribution of self reported oral contraceptive use differed between women presented in ES and LS (*P*\< 0.001) (Table [3](#T3){ref-type="table"}).

###### 

General characteristics of breast cancer cases

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables by level                                   Total distribution   Clinical Stage I&II   Clinical Stage III&IV   ES vs. LS\                        
                                                                                                                          *P*-value                         
  ---------------------------------------------------- -------------------- --------------------- ----------------------- ------------ ------------- ------ -------------
  **Age at Diagnosis (Years)**\                                                                                                                             
  **(4211, 2554, 901)**                                                                                                                                     

   Mean ± SD                                           48.7 ± 10.5          \--                   49.1 ± 10.4             \--          48.8 ± 10.3   \--    0.345^a^

   Range                                               21\~86               \--                   21\~86                  \--          21\~85        \--    

   ≤ 29                                                80                   1.9                   38                      1.5          17            1.9    

   30-39                                               710                  16.9                  404                     15.8         144           16.0   

   40-49                                               1624                 38.6                  987                     38.7         341           37.9   0.088^b^

   50-59                                               1147                 27.2                  693                     27.1         276           30.6   

   ≥ 60                                                650                  15.4                  432                     16.9         123           13.7   

  **Body Mass Index**\                                                                                                                                      
  **(3281, 2107, 646 )**                                                                                                                                    

   Mean ± SD                                           23.4 ± 3.3           \--                   23.3 ± 3.2              \--          23.5 ± 3.4    \--    0.173^a^

   Range                                               12.8\~39.4           \--                   14.7\~36.1              \--          12.8\~39.4    \--    

   Underweight (≤ 18.49)                               140                  4.3                   74                      3.5          30            4.6    

   Normal Weight (18.50\~24.99)                        2217                 67.6                  1461                    69.3         424           65.6   0.196^b^

   Overweight (25.00\~29.99)                           818                  24.9                  511                     24.3         167           25.9   

   Obesity (≥ 30.00)                                   106                  3.2                   61                      2.9          25            3.9    

  **Occupation (3623, 2192, 796)**                                                                                                                          

   Housewife                                           173                  4.8                   127                     5.8          26            3.3    

   Manual Worker                                       1893                 52.3                  1099                    50.1         474           59.6   \< 0.001^b^

   Mental Worker                                       1028                 28.4                  659                     30.1         189           23.7   

   Others                                              529                  14.6                  307                     14.0         107           13.4   

  **Education (2091, 1315, 486)**                                                                                                                           

   None                                                186                  8.9                   112                     8.5          55            11.3   

   Primary School                                      462                  22.1                  273                     20.8         115           23.7   

   Middle School                                       606                  29.0                  370                     28.1         141           29.0   0.008^b^

   High School                                         441                  21.1                  280                     21.3         106           21.8   

   University and above                                396                  18.9                  280                     21.3         69            14.2   

  **Marital Status (4193, 2548, 899)**                                                                                                                      

   Single                                              51                   1.2                   25                      1.0          14            1.6    

   Married                                             4090                 97.5                  2482                    97.4         878           97.7   0.073^b^

   Widowed/Divorced                                    52                   1.2                   41                      1.6          7             0.8    

  **Region (4211, 2554, 901)\***                                                                                                                            

   More Developed                                      1851                 44.0                  1127                    44.1         389           43.2   0.620^b^

   Less Developed                                      2360                 56.0                  1427                    55.9         512           56.8   

  **Smoking History (4211, 2554, 901)**                                                                                                                     

   Never                                               2468                 58.6                  1451                    56.8         596           66.2   

   Used                                                47                   1.1                   37                      1.5          9             1.0    \< 0.001^c^

   current                                             12                   0.3                   5                       0.2          3             0.3    

   Unknown                                             1684                 40.0                  1061                    41.5         293           32.5   

  **Alcohol Drinking History**\                                                                                                                             
  **(4211, 2554, 901)**                                                                                                                                     

   Never                                               2427                 57.6                  1415                    55.4         598           66.4   

   Used                                                82                   2.0                   70                      2.7          6             0.7    \< 0.001^c^

   Now                                                 13                   0.3                   7                       0.3          4             0.4    

   Unknown                                             1689                 40.1                  1062                    41.6         293           32.5   

  **Breast Cancer Family History (4128, 2517, 882)**                                                                                                        

   Yes                                                 144                  3.5                   96                      3.8          21            2.4    0.045^b^

   No                                                  3984                 96.5                  2421                    96.2         861           97.6   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Student\'s t-test

^b^Chi-square test

^c^Fisher\'s exact test

\* More Developed Regions: North, South, and East

Less Developed Regions: North-East, Central, North-West, South-West.

###### 

Reproductive characteristics of breast cancer cases

  --------------------------------------------------------------------------------------------------------------------------------------------------
  Variables by level                   Total distribution\   Clinical Stage I&II\   Clinical Stage III&IV\   ES vs. LS\                
                                       (N = 4211)            (N = 2554)             (N = 901)                *P*-value                 
  ------------------------------------ --------------------- ---------------------- ------------------------ ------------ ----- ------ -------------
  **Menopausal Status**\                                                                                                               
  **(4211, 2554, 901)**                                                                                                                

   Pre-menopausal                      2649                  62.9                   1585                     62.1         541   60.0   0.285^b^

   Post-menopausal                     1562                  37.1                   969                      37.9         360   40.0   

  **Age at Menopause (Years)**\                                                                                                        
  **(1562, 969, 360) \*\***                                                                                                            

   ≤ 50                                1017                  65.1                   631                      65.1         239   66.4   0.665^b^

   \> 50                               545                   34.9                   338                      34.9         121   33.6   

  **Age at Menarche (Years)**\                                                                                                         
  **(150, 80, 50)**                                                                                                                    

   7\~11                               3                     2.0                    0                        0.0          2     4.0    

   12\~13                              37                    24.7                   22                       27.5         11    22.0   0.200^c^

   ≥ 14                                110                   73.3                   58                       72.5         37    74.0   

  **Age at First Delivery (Years)**\                                                                                                   
  **(2021, 1372, 357 )**                                                                                                               

   \< 20                               33                    1.6                    15                       1.1          11    3.1    

   20\~24                              917                   45.4                   638                      46.5         153   42.9   0.030^b^

   25\~29                              940                   46.5                   632                      46.1         166   46.5   

   ≥ 30                                131                   6.5                    87                       6.3          27    7.6    

  **Number of Live Births**\                                                                                                           
  **(3947, 2428, 807)**                                                                                                                

   0                                   99                    2.5                    44                       1.8          17    2.1    

   1                                   1889                  47.9                   1177                     48.5         348   43.1   

   2                                   1228                  31.1                   767                      31.6         269   33.3   0.082^b^

   3                                   452                   11.5                   271                      11.2         110   13.6   

   ≥ 4                                 279                   7.1                    169                      7.0          63    7.8    

  **Breast Feeding History**\                                                                                                          
  **(2671, 1754, 492)**                                                                                                                

   Yes                                 2414                  90.4                   1591                     90.7         445   90.5   0.861^b^

   No                                  257                   9.6                    163                      9.3          47    9.5    

  **O.C Consumption History**\                                                                                                         
  **(4211, 2554, 901)**                                                                                                                

   Never                               543                   12.9                   376                      14.7         98    10.9   

   Used                                325                   7.7                    278                      10.9         36    4.0    \< 0.001^c^

   Now                                 11                    0.3                    10                       0.4          1     0.1    

   Unknown                             3332                  79.1                   1890                     74.0         766   85.0   
  --------------------------------------------------------------------------------------------------------------------------------------------------

^a^Student\'s t-test

^b^Chi-square test

^c^Fisher\'s exact test

\*\* Median age of menopause has been used to create the two age-categories.

Table [4](#T4){ref-type="table"} illustrates the clinical and pathologic characteristics of patients. The average mass size by CBE was 31.3 mm (s.d. = 17.8 mm) and patients in ES were more likely to be examined of having masses less than 50 mm (*P*\< 0.001) and had a much lower chance of having local invasion (*P*\< 0.001). Patients in LS were more likely to have positive mammography results (*P*= 0.001) and positive ultrasound diagnosis (*P*= 0.015). Over the 10 years, invasive ductal carcinoma remained the dominant pathologic subtype (86.5%). Among the 3,534 patients that had estrogen receptor (ER) and progesterone receptor (PR) information, less than 10% (9.5%) were only ER positive and PR negative; 10.4% were positive with PR but negative with ER; about half (47.9%) were both ER and PR positive and 32.2% were negative with both. HER-2 information was available for 2,849 patients and the majority (74.2%) of them were HER-2 negative (Table [4](#T4){ref-type="table"}). Among the 4,211 cases, the majority (60.6% (2,554/4,211)) had ES breast cancer, and less than a quarter (21.4% (901/4,211)) had LS disease. About 18% (756/4,211) of cases did not have staging information. The stage distribution differed between the less developed and more developed regions of China (*P*\< 0.001). More stage I patients (19.9%) were presented in more developed regions than that (12.7%) in less developed regions and the reverse was seen for stage IV patients (Table [5](#T5){ref-type="table"}).

###### 

Clinical and pathologic characteristics of breast cancer cases

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables by level                                           Total distribution   Clinical Stage I&II   Clinical Stage III&IV   ES vs.LS\                        
                                                                                                                                  *P*-value                        
  ------------------------------------------------------------ -------------------- --------------------- ----------------------- ----------- ------------- ------ -------------
  **Palpable Tumor Location by CBE(4211, 2554, 901)**                                                                                                              

   Left                                                        2189                 52.0                  1327                    52.0        477           52.9   

   Right                                                       1995                 47.4                  1213                    47.5        419           46.5   0.868^c^

   Non-palpable                                                27                   0.6                   14                      0.5         5             0.6    

  **Mass Size by CBE**\                                                                                                                                            
  **(3555, 2434, 825)**                                                                                                                                            

   Mean ± SD                                                   31.3 ± 17.8          \--                   27.7 ± 12.8             \--         40.7 ± 23.4   \--    \< 0.001^a^

   Range                                                       0\~250               \--                   0\~150                  \--         0\~250        \--    

   \< 50 mm                                                    3036                 85.4                  2247                    92.3        559           67.8   

   ≥ 50 mm                                                     519                  14.6                  187\*                   7.7         266           32.2   \< 0.001^b^

  **Local Invasion**\                                                                                                                                              
  **(3663, 2428, 826)**                                                                                                                                            

   Yes                                                         183                  5.0                   45                      1.9         106           12.8   \< 0.001^b^

   No                                                          3480                 95.0                  2383                    98.1        720           87.2   

  **Mammography Diagnosis (1275, 877, 286)\*\***                                                                                                                   

   Positive                                                    1094                 85.8                  750                     85.5        266           93.0   0.001^b^

   Negative                                                    181                  14.2                  127                     14.5        20            7.0    

  **Ultrasound Diagnosis (2253, 1629, 409 )\*\***                                                                                                                  

   Positive                                                    2006                 89.0                  1461                    89.7        383           93.6   0.015^b^

   Negative                                                    247                  11.0                  168                     10.3        26            6.4    

  **Postoperative Pathological Diagnosis (4014, 2540, 877)**                                                                                                       

   Carcinoma in Situ(CIS)                                      143                  3.6                   77                      3.0         5             0.6    

   Invasive Ductal\                                            3471                 86.5                  2203                    86.7        801           91.3   \< 0.001^c^
  Carcinoma                                                                                                                                                        

   Other Type Invasive\                                        385                  9.6                   252                     9.9         69            7.9    
  Carcinoma                                                                                                                                                        

   Others                                                      15                   0.3                   8                       0.3         2             0.2    

  **ER/PR Status**\                                                                                                                                                
  **(3534, 2316, 758)**                                                                                                                                            

   ER+&PR+                                                     1691                 47.9                  1148                    49.6        340           44.9   

   ER+&PR-                                                     337                  9.5                   204                     8.8         84            11.1   0.070^b^

   ER-&PR+                                                     367                  10.4                  230                     9.9         86            11.4   

   ER-&PR-                                                     1139                 32.2                  734                     31.7        248           32.7   

  **HER-2 Status**\                                                                                                                                                
  **(2849, 1935, 582)**                                                                                                                                            

   HER-2 +                                                     736                  25.8                  504                     26.0        154           26.5   0.842^b^

   HER-2 -                                                     2113                 74.2                  1431                    74.0        428           73.5   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Student\'s t-test

^b^Chi-square test

^c^Fisher\'s exact test

\* Among the 187 women with palpable lumps ≥ 50 mm by CBE, 101 were found to have smaller lumps based on the postoperative evaluation and were categorized as stage I or stage IIA (16 as stage I; 85 as stage IIA). The rest 86 were categorized as stage IIB.

\*\* Negative: negative, benign, and possibly benign finding; Positive: malignant suspicious, malignant.

###### 

Stage distribution of breast cancer cases by region

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical\   Total   More Developed Regions\*\*   Less Developed Regions\*\*\*   *P\**                                                                                                            
  Stage                                                                                                                                                                                            
  ----------- ------- ---------------------------- ------------------------------ ------- ----- ------ ----- ------ ----- ------ ----- ------ ----- ------ ----- ------ ----- ------ ------ ------ ----------
  Stage I     663     15.7                         172                            26.8    98    16.2   95    15.7   365   19.9   131   15.8   73    13.4   77    15.9   17    3.4    298    12.7   

  Stage II    1891    44.9                         280                            43.7    243   40.2   239   39.4   762   41.6   323   38.8   400   73.3   170   35.2   236   47.3   1129   48.3   

  Stage III   788     18.7                         93                             14.5    117   19.4   152   25.1   362   19.8   119   14.3   53    9.7    127   26.3   127   25.5   426    18.2   \< 0.001

  Stage IV    113     2.7                          2                              0.3     20    3.3    5     0.8    27    1.5    4     0.5    3     0.6    56    11.6   23    4.6    86     3.7    

  Unknown     756     18.0                         94                             14.7    126   20.9   115   19.0   335   18.3   255   30.7   17    3.1    53    11.0   96    19.2   421    18.0   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Stage distribution in more developed regions vs. less developed regions

\*\* More Developed Regions: North, South, and East

\*\*\*Less Developed Regions: Northeast, Central, North-West, South-West.

Treatment Patterns
------------------

Among all breast cancer cases, the majority (96.9% (4,078/4,211)) had undergone surgery procedures and radical mastectomy was the predominant option (88.8% (3,740/4,211). A minority of women (5.5% (231/4,211)) received breast conservative surgery. Chemotherapy was the second most important treatment option (81.4% (3,428/4,211) for breast cancer patients in China. By comparison, radiotherapy (22.6% (952/4,211)) and endocrine therapy (38.0% (1,599/4,211)) were not as popular as surgery and chemotherapy (Table [6](#T6){ref-type="table"}).

###### 

Treatment patterns of breast cancer cases

  Therapy                        Total   
  ------------------------------ ------- ------
  **Surgery**                            
   No                            107     2.5
   Radical Mastectomy            3740    88.8
   Breast Conservative Surgery   231     5.5
   Simple Mastectomy             46      1.1
   Others                        61      1.5
   Unknown                       26      0.6
  **Radiotherapy**                       
   No                            2723    64.7
   Yes                           952     22.6
   Unknown                       536     12.7
  **Chemotherapy**                       
   No                            626     14.9
   Yes                           3428    81.4
   Unknown                       157     3.7
  **Endocrine Therapy**                  
   No                            2092    49.7
   Yes                           1599    38.0
   Unknown                       520     12.4

Discussion
==========

This was the first geographically representative epidemiologic study of breast cancer in China and included more than 4,000 patients over its course. This study, via its inclusion of a large number of sites across all seven traditional regions of China, facilitated a thorough assessment of breast cancer patient characteristics, treatment allocation, and allowing a unique analysis of possible regional variations in these aspects of breast epidemiology and management across the entire country. It also helps to determine levels of unmet medical need and identify regions of high risk for breast cancer within China.

All patients included in our study were ethnically Chinese. Their clinical characteristics were significantly different from those of the women in western countries. The mean age at diagnosis was 48.7 years, and this was similar to the findings from other regional studies within China \[[@B9]-[@B14]\]. It was also in agreement with reports from other Asian countries such as Singapore, India and also similar to Saudi Arabia, all of which were around the mid-40s. This was about a decade earlier than what is reported for Western Caucasian women \[[@B15]-[@B19]\]. The reasons for the distinctions remain obscure, but four hypotheses may explain. First, older Asians including Chinese women had been less exposed to estrogen related risk factors thus have been less susceptible to breast cancer than their younger counterparts. Second, younger women were more genetically predisposed to breast cancer. Third, younger women were more aware of breast cancer. They have broader access to medical care as there is no nationwide organized screening program in China as well as in the majority of the modernizing Asian countries. Fourth, mammography has been used among older women in the population based mammography screening in Western countries. This may partly account for why breast cancer clusters peak around 60-69 years in Western countries.

In this study, 60.6% of the patients had early stage breast cancer and 21.4%% had late stage disease. The incidence of early stage disease on presentation was lower than the data from China Tianjin (72.3%) \[[@B14]\], Taiwan (78.3%) \[[@B13]\] and Singapore (79%) \[[@B20]\], and much lower than the western countries such as the United States (85%) \[[@B21]\]. A study from Hong Kong which focused on a selected group of affluent Chinese patients reported an 88.9% of early stage cases \[[@B19]\]. While in the African countries, large proportions of patients presenting at late stage were reported, early stage cases accounted for only 9.27% to 42.7% \[[@B22]-[@B25]\]. The vast difference between regions and countries may due to the absence of a nationwide breast cancer screening program in developing countries including China, whereas such programs are fully or partly implemented in the majority of developed countries \[[@B26]\]. The findings of our study also suggest that women who were mental workers and had at least a university education were more likely to present breast cancer at early stage. This is in consistent with reports from a review article that socioeconomic disparities including low family income, poor educational attainment and impaired access to healthcare etc were related to the more advanced disease at diagnosis and poorer prognosis \[[@B27]\].

ER positive breast cancers are acknowledged to be related to a better prognosis than those that are ER negative \[[@B28]\] as they respond better to hormone therapy \[[@B29]\]. HER-2 positive breast cancers are more aggressive and require more expensive therapy \[[@B30]\]. In our study, 57.4% (2,028/3,534) were ER positive and 25.8% (736/2,849) were HER-2 positive. The ER status of Chinese breast cancer was documented previously and the positivity varied from 45.3% to 67% \[[@B31]-[@B35]\]. When compared with data from developed countries, the positivity from our study is significantly lower \[[@B36],[@B37]\]. The prevalence of HER-2 has been documented to be 27.9% in a Chinese study \[[@B35]\] and 15% in one study from the United States \[[@B38]\]. It suggests that breast cancer in Chinese women may be more aggressive than those in the developed countries, but those differences may also be explained by the un-uniformed tests used, different cut-off value referred, and bias from the age distribution in various studies. Although our study sample is representative, the tests were done retrospectively and different methods and protocols were conducted. Further study using a representative sample and standard protocol to understand the status of ER/PR/HER-2 status in Chinese breast cancer is necessary and would make it more comparable.

Surgery was the most common treatment in Chinese female breast cancer patients followed by chemotherapy. Among all surgery procedures, radical mastectomy was widely perceived as the only curative treatment, which is consistent with a study from Hong Kong \[[@B39]\]. Options for radiotherapy and endocrine therapy were much less, which indicates that adjuvant therapy, especially radiotherapy and endocrine therapy are of great unmet needs. Further analysis and studies were necessary to understand the patterns of treatment based on detailed information of treatment indications such as tumor size, lymph node involvement, final margins, and ER status.

These findings will need to be considered in light of the study\'s strengths and weaknesses. The primary strengths of this study are (1) the large number of patients included and (2) the geographic representativeness of the included sites. The main potential study limitations are (1) selection bias may exist in the catchment of breast cancer patients in the selected hospitals as no less elite hospitals as comparison were selected from the same regions. (2) There is no comparison group to compare the risk factors of developing breast cancer and (3) data quality is dependent on the thoroughness of the clinician\'s documentation of medical history, treatment, and outcomes.

Conclusion
==========

The Chinese breast cancer multi-center clinical epidemiologic study represents the first geographically representative study of breast cancer in China to understand patterns of breast cancer characteristics, therapy use and knowledge of continuing unmet needs for breast cancer by retrospectively reviewing the existed clinical data.

The younger age of breast cancer onset among Chinese women and more advanced tumor stages pose a great challenge for Chinese government on breast cancer control. The higher proportion of ER+/PR+ breast cancer patients is a great challenge for breast cancer management in China. The Government oriented campaign to raise awareness will need to be expanded and continued. The most updated clinical guideline will also need to be disseminated to doctors at all levels to benefit the patients, ultimately improving the prognosis in Chinese breast cancer patients.
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